Abstract
Epicardial coronary artery diameter (ECAD), coronary blood flow velocity (CBFV), and coronary flow velocity reserve (CFVR) were analyzed at baseline and after a 500 μg i.e. bolus of diltiazem in nonstenotic coronary arteries of awake humans. Furthermore, patients (n = 25) were first randomized to pretreatment either with placebo (n = 12) or isosorbide dinitrate (0.5 μg/kg/min infusion) (n = 13). Diltiazem resulted in a significant increase in epicardial diameter (+ 10%; p = 0.001) and in coronary blood How (CBF) (+ 30%; p = 0.0001). Whereas basal CBFV only slightly increased (+7% NS), there was a significant fall in CFVR (− 11%; p = 0.001). The increase in coronary diameter and CBF after administration of i.e. diltiazem was comparable in placebo- and nitrate-pretreated patients. The decrease in CFVR, however, was restricted to the placebo-pretreated patients (−21%; p = 0.0004). Apparently, diltiazem attenuated the CFVR but only in the absence of nitrates. Thus, diltiazem i.e. appears to enhance myocardial oxygen supply without deleterious effects on the distal coronary perfusion pressure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.